NO20075361L - Fremgangsmate og preparat for behandling av slimhinneforstyrrelser - Google Patents

Fremgangsmate og preparat for behandling av slimhinneforstyrrelser

Info

Publication number
NO20075361L
NO20075361L NO20075361A NO20075361A NO20075361L NO 20075361 L NO20075361 L NO 20075361L NO 20075361 A NO20075361 A NO 20075361A NO 20075361 A NO20075361 A NO 20075361A NO 20075361 L NO20075361 L NO 20075361L
Authority
NO
Norway
Prior art keywords
treatment
mucosal disorders
preparation
mucosal
prostaglandin compound
Prior art date
Application number
NO20075361A
Other languages
English (en)
Norwegian (no)
Inventor
Ryuji Ueno
Sachiko Kuno
Anthony T Blikslager
Adam J Moeser
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Publication of NO20075361L publication Critical patent/NO20075361L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20075361A 2005-03-21 2007-10-19 Fremgangsmate og preparat for behandling av slimhinneforstyrrelser NO20075361L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66320005P 2005-03-21 2005-03-21
US67992005P 2005-05-11 2005-05-11
US72197605P 2005-09-30 2005-09-30
PCT/JP2006/306380 WO2006101244A2 (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders

Publications (1)

Publication Number Publication Date
NO20075361L true NO20075361L (no) 2007-12-20

Family

ID=36754577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075361A NO20075361L (no) 2005-03-21 2007-10-19 Fremgangsmate og preparat for behandling av slimhinneforstyrrelser

Country Status (14)

Country Link
US (1) US20060281818A1 (es)
EP (3) EP2384790A3 (es)
JP (2) JP5219797B2 (es)
KR (2) KR20140072102A (es)
CN (1) CN103948603A (es)
AU (1) AU2006225515B2 (es)
BR (1) BRPI0609672A2 (es)
CA (2) CA2831416C (es)
ES (1) ES2592283T3 (es)
IL (1) IL185861A (es)
MX (1) MX2007011645A (es)
NO (1) NO20075361L (es)
NZ (3) NZ597857A (es)
WO (1) WO2006101244A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
EP2214496A4 (en) * 2007-10-25 2012-06-06 Phytoceutica Inc USE OF PHY906 AS TREATMENT FOR INFLAMMATORY ENDURANCE AND / OR IRRITATION
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
RU2011153196A (ru) * 2009-05-27 2013-07-10 Сукампо Аг Фармацевтическая композиция, содержащая производные простагландинов, для применения в модулировании опосредованных клаудином функций и лечении дерматологических нарушений
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
CN107028952A (zh) * 2011-04-19 2017-08-11 苏坎波公司 用于调节细胞因子活性的方法
WO2012148002A1 (en) * 2011-04-27 2012-11-01 Sucampo Ag Method for modulating ion transporter
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease
US10738089B2 (en) * 2015-05-06 2020-08-11 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2024217532A1 (zh) * 2023-04-20 2024-10-24 中南大学湘雅二医院 Carboprost在制备抗肿瘤药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンd類似化合物
JPS591463A (ja) * 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンd類似化合物
FR2608924B1 (fr) * 1986-12-29 1990-07-20 Pasteur Institut Compositions therapeutiques contenant des derives soufres de prostaglandines, nouveaux derives soufres et leur procede de preparation
US5428062A (en) * 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) * 1988-07-19 1997-02-05 小野薬品工業株式会社 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (es) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5234858A (en) 1990-11-16 1993-08-10 Micron Technology, Inc. Stacked surrounding wall capacitor
KR940007277B1 (ko) 1992-02-14 1994-08-12 한국과학기술원 2차 전지 전극용 수소 저장 합금
US5376034A (en) 1992-05-27 1994-12-27 Brunswick Corporation Marine drive exhaust system
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
DK0857718T3 (da) 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US6919082B2 (en) * 2001-02-13 2005-07-19 Kirin Beer Kabushiki Kaisha Pharmacological composition containing yeast cell wall fraction
GB2375349A (en) * 2001-02-13 2002-11-13 Glaxo Group Ltd Chloride intracellular channel-related proteins
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods
JP4786866B2 (ja) * 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
CA2510051C (en) * 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders

Also Published As

Publication number Publication date
EP1861169B1 (en) 2016-05-11
KR20080012266A (ko) 2008-02-11
CN103948603A (zh) 2014-07-30
WO2006101244A2 (en) 2006-09-28
JP2008533195A (ja) 2008-08-21
JP5777574B2 (ja) 2015-09-09
JP5219797B2 (ja) 2013-06-26
AU2006225515A8 (en) 2006-09-28
NZ588878A (en) 2012-05-25
IL185861A0 (en) 2008-01-06
EP2384790A3 (en) 2011-12-28
CA2831416A1 (en) 2006-09-28
KR101456298B1 (ko) 2014-11-03
JP2012180380A (ja) 2012-09-20
KR20140072102A (ko) 2014-06-12
AU2006225515B2 (en) 2012-02-02
CA2831416C (en) 2016-12-13
EP2384791A3 (en) 2011-12-28
US20060281818A1 (en) 2006-12-14
NZ597857A (en) 2013-08-30
ES2592283T3 (es) 2016-11-29
AU2006225515A1 (en) 2006-09-28
BRPI0609672A2 (pt) 2010-04-20
NZ562351A (en) 2010-12-24
EP2384791A2 (en) 2011-11-09
EP2384791B1 (en) 2016-06-15
EP2384790A2 (en) 2011-11-09
IL185861A (en) 2015-06-30
MX2007011645A (es) 2007-11-16
WO2006101244A3 (en) 2007-02-08
EP1861169A2 (en) 2007-12-05
CA2601158A1 (en) 2006-09-28
CA2601158C (en) 2015-10-13

Similar Documents

Publication Publication Date Title
NO20075361L (no) Fremgangsmate og preparat for behandling av slimhinneforstyrrelser
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20072290L (no) Organiske forbindelser.
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20081421L (no) Midler for hindring og behandling av forstyrrelser som involverer modulering av RYR-reseptorer
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20075304L (no) Metode for avtagende forkalkning
NO20071090L (no) Behandling av pulmonal hypertensjon ved inhalert iloprost med en mikropartikkelformulering.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
EA201170703A1 (ru) Производные адамантилбензамида
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20074332L (no) Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser
EA201100755A1 (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
NO20073854L (no) Doseringsform og fremgangsmate for vedvarende frigjoring av en substituert pyrazinforbindelse
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
DK1670778T3 (da) Omlejrede pentanoler, en fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelsehæmmende

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application